Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 4/20 | 0.54 |
| ▸ | SRD5A1 | P18405 | 3/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8134829 | 1.00 | SRD5A2 (0.54) | SRD5A2SRD5A1AR | |
| SCHEMBL1949188 | 0.83 | SRD5A1 (0.51) | SRD5A2SRD5A1AR | |
| SCHEMBL8127744 | 0.81 | SRD5A2 (0.53) | SRD5A2SRD5A1 | |
| SCHEMBL8132084 | 0.81 | SRD5A2 (0.53) | SRD5A2SRD5A1 | |
| SCHEMBL8127746 | 0.81 | SRD5A2 (0.53) | SRD5A2SRD5A1 | |
| SCHEMBL8721495 | 0.80 | SRD5A1 (0.57) | SRD5A2SRD5A1AR | |
| SCHEMBL5682764 | 0.80 | SRD5A2 (0.64) | SRD5A2SRD5A1AR | |
| SCHEMBL4269548 | 0.80 | SRD5A2 (0.64) | SRD5A2SRD5A1AR | |
| SCHEMBL7596381 | 0.80 | SRD5A1 (0.57) | SRD5A2SRD5A1AR | |
| SCHEMBL4269554 | 0.80 | SRD5A2 (0.64) | SRD5A2SRD5A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2011-06-09 | — | — | US | claimed |
| US-20090123571-A1 | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | MERCK SHARP & DOHME CORP. | 2009-05-14 | — | — | US | claimed |
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2011-06-09 | — | — | US | disclosed |
| US-6143887-A | REACTING A 16-METHYLSULFONATE-4-AZA-ANDROSTANONES WITH HYDROXY SUBSTITUTED AROMATIC OR HETEROAROMATIC COMPOUND AND CESIUM CARBONATE IN PRESENCE OF A POLAR APROTIC SOLVENT | MERCK & CO., INC. (US) | 2000-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090123571-A1 | Method of treating men with testosterone supplement and 5alpha-reductase inhibitor | ADRA1D, ADRB1, AGER | SRD5A2 26/4885SRD5A1 17/4885AR 22/4885 |
| US-20110136769-A1 | METHOD OF TREATING MEN WITH TESTOSTERONE SUPPLEMENT AND 5ALPHA-REDUCTASE INHIBITOR | ADRA1D, ADRB1, AGER | SRD5A2 26/4885SRD5A1 17/4885AR 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.